A recent study published in the Annals of Internal Medicine reveals a growing trend in the prescription of GLP-1 medications to patients without diabetes, at a time when new prescriptions for those with diabetes are on the decline. Researchers from Cedars-Sinai Medical Center analyzed the medical records of 45 million Americans from 2011 to 2023 and found that the percentage of new GLP-1 users with type 2 diabetes decreased from nearly 90% to over 70%. Conversely, the share of new users without diabetes grew from 10% to 25% in the same period.
GLP-1 drugs, including Zepbound, Mounjaro, Wegovy, and Ozempic, mimic a hormone that helps regulate blood sugar and suppress appetite. While these medications were initially approved for treating type 2 diabetes, the approval of Wegovy for weight loss in 2021 has led to increasing interest among healthcare providers looking for effective obesity treatments. Yee Hui Yeo, co-first author of the study, noted that this shift reflects a significant change in public health perspectives, but it also raises concerns regarding possible shortages in medication for diabetic patients.
The intensified demand has posed challenges for pharmaceutical companies like Novo Nordisk and Eli Lilly, which are struggling to meet the soaring needs for these treatments. Analysts predict that the global market for GLP-1 drugs could grow to $105 billion by 2030, with about 31.5 million Americans anticipated to be using these medications by 2035.
Though rising demand presents hurdles for availability, it underscores a growing recognition of obesity as a critical health issue, potentially leading to long-term improvements in overall public health if managed effectively. With companies investing heavily in production, there is hope that sufficient supplies will eventually be met to cater to both individuals with diabetes and those seeking weight loss solutions.
This turn of events indicates an evolution in the way health professionals are addressing obesity and related health challenges, suggesting a more comprehensive approach to patient care in the future.